PR 000608
Alternative Names: PR 608Latest Information Update: 05 Oct 1998
At a glance
- Originator POLA
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Dopamine uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 05 Oct 1998 No-Development-Reported for Parkinson's disease in Japan (Unknown route)
- 30 Dec 1996 Preclinical development for Parkinson's disease in Japan (Unknown route)